Aviragen Therapeutics, Inc. News (NASDAQ:AVIR)

DateTimeSource
Headline
09/14/20164:01PMGLOBEAviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2016 Financial Results
ATLANTA, Sept. 14, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the fourth quarter and 2016 fiscal year ended June 30, 2016, and also provided an update on recent corporate and clinical developments. “Over the last twelve months we have made significant... More...>>
09/13/20167:00PMGLOBEAviragen Therapeutics Announces Rescheduled Date and Time of Fourth Quarter and Fiscal Year 2016 Financial Results on Septemb...
ATLANTA, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Wednesday, September 14, 2016 at 4:30 p.m. ET to review... More...>>
09/07/20169:00AMGLOBEAviragen Therapeutics to Present at Upcoming Investor Conferences
ATLANTA, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that Aviragen's CEO & President Joseph Patti, PhD will present a corporate overview at the... More...>>
09/06/20166:30PMGLOBEAviragen Therapeutics Announces Inducement Grant for New Employees
ATLANTA, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that the Company has granted two new hires options to purchase an aggregate of 125,000 shares of the... More...>>
09/06/20165:34PMGLOBEAviragen Therapeutics Announces Schedule Change for Fourth Quarter and Fiscal Year End 2016 Financial Results Conference Call...
ATLANTA, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that it is delaying the time of its fourth quarter and fiscal year end 2016 earnings conference... More...>>
09/01/20169:00AMGLOBEAviragen Therapeutics to Host Conference Call to Report Fourth Quarter and Fiscal Year 2016 Financial Results on September 8,...
ATLANTA, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, September 8, 2016 at 4:30 p.m. ET to review... More...>>
07/12/20167:00AMGLOBEAviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial
ATLANTA, July 12, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced it is resuming enrollment in its Phase 2a challenge study of BTA585, an oral fusion inhibitor in development... More...>>
07/05/20167:00AMGLOBEAviragen Therapeutics and Georgia State University Research Foundation Enter Exclusive License and Sponsored Research Agreeme...
ATLANTA, July 05, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that it has entered into an exclusive, worldwide license and sponsored research agreement with Georgia... More...>>
07/01/20164:01PMGLOBEAviragen Therapeutics Announces Inducement Grant for New Employee
ATLANTA, July 01, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that the compensation committee of the Company’s Board of Directors granted to Jonas Niaura, Vice... More...>>
06/28/20169:00AMGLOBEAviragen Therapeutics Announces the Appointment of Jonas Niaura as Vice President, Corporate Development and Strategy
ATLANTA, June 28, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced the appointment of Jonas Niaura as Vice President, Corporate Development and Strategy. “Jonas brings to Aviragen considerable business development... More...>>
05/26/20164:30PMGLOBEAviragen Therapeutics Provides Update on Phase 2a Trial of BTA585 for the Treatment of RSV Infections
ATLANTA, May 26, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that it has voluntarily decided to delay further enrollment in the Phase 2a trial of BTA585 for the treatment... More...>>
05/05/20164:01PMGLOBEAviragen Therapeutics Reports Third Quarter Fiscal Year 2016 Financial Results
ATLANTA, May 05, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.) today announced its financial results for the three month period ended March 31, 2016, which is the third quarter of the Company's 2016 fiscal year, and also provided an update on recent corporate... More...>>
04/28/20164:01PMGLOBEAviragen Therapeutics to Host Conference Call to Report Third Quarter Fiscal Year 2016 Financial Results on May 5, 2016
ATLANTA, April 28, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.) a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, May 5, 2016 at 4:30 p.m. ET to review the Company’s... More...>>
04/28/201611:46AMGLOBEAviragen Therapeutics Completes Royalty Deal With HealthCare Royalty Partners for Proceeds of $20 Million
ATLANTA, April 25, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.) a pharmaceutical company that is developing the next generation of antivirals, today announced that it has signed a definitive agreement to receive a cash payment of $20 million from HealthCare Royalty... More...>>
04/14/20164:01PMGLOBEAviragen Therapeutics to Participate in FBR & Co. Healthcare Series Focused on Infectious Diseases
ATLANTA, April 14, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc., (NASDAQ:AVIR), formerly Biota Pharmaceuticals, Inc., today announced that Joseph Patti, PhD, President & CEO of Aviragen Therapeutics, will participate in a panel discussion titled, “Notable Emerging Anti-Viral Agents” as part of the FBR &... More...>>
04/12/20167:00AMGLOBEBiota Pharmaceuticals, Inc. Announces Name Change to Aviragen Therapeutics, Inc. (NASDAQ: AVIR)
ATLANTA, April 12, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced that the Company has changed its name to Aviragen Therapeutics, Inc., (“Aviragen Therapeutics”), a pharmaceutical company focused on the development of the next generation of direct-acting antivirals that address infections... More...>>
04/12/20167:00AMGLOBEBiota Pharmaceuticals, Inc. Announces Name Change to Aviragen Therapeutics, Inc. (NASDAQ: AVIR)
ATLANTA, April 12, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced that the Company has changed its name to Aviragen Therapeutics, Inc., (“Aviragen Therapeutics”), a pharmaceutical company focused on the development of the next generation of direct-acting antivirals that address infections... More...>>
04/11/20167:00AMGLOBEBiota Initiates Phase 2a Efficacy Study of BTA585 for the Treatment of RSV Infections
ATLANTA, April 11, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, today announced the initiation of its Phase 2a challenge study of BTA585... More...>>
04/06/20169:00AMGLOBEBiota Pharmaceuticals to Present at 15th Annual Needham Healthcare Conference
ATLANTA, April 06, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota’s CEO & President Joseph Patti, PhD will... More...>>
03/17/20166:30AMGLOBEBiota Pharmaceuticals Announces Sale of Antibiotic Assets to Spero Therapeutics
ATLANTA, March 17, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced that it has completed the sale of assets related to its broad spectrum antibiotic program to a newly formed subsidiary of Spero Therapeutics, LLC, a Cambridge-based biopharmaceutical company founded to develop novel therapies... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20160927 15:33:37